D

Alto Neuroscience, Inc. ANRO

$27.12 -$2.42-8.19% NYSE
Recommendation
Dividend Power Score
Day's Range
$26.94$29.54
Latest Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
My Lists My Alerts
Access our Premium Ratings
Get Access

ANRO Rating

Reward
Risk

ANRO Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

ANRO Company Overview

Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biotechnology company focused on developing precision psychiatry treatments for mental health conditions such as major depressive disorder (MDD), bipolar depression, schizophrenia, and post-traumatic stress disorder (PTSD). The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, emphasizing biomarker-driven drug development intended to match patients with therapies based on measurable biological and neurophysiological characteristics. Its primary revenue and enterprise value drivers are tied to the advancement of its clinical-stage pipeline, intellectual property portfolio, and strategic development capabilities rather than commercialized products.

Alto Neuroscience was founded in 2019 by psychiatrist and neuroscientist Dr. Amit Etkin, who previously led research efforts at Stanford University focused on neurobiology and psychiatric disorders. The company evolved around the concept that psychiatric drug development could achieve improved clinical outcomes through patient stratification using biomarkers such as electroencephalography (EEG), neurocognitive assessments, digital phenotyping, and other objective measures. Alto completed its initial public offering in 2024 and has positioned itself as a precision medicine-focused CNS developer seeking differentiation from traditional psychiatry drug companies that rely on broader population-based clinical approaches.

Data compiled by narrative technology. May contain errors.
Sector

ANRO Income Statement

Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

ANRO Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

ANRO Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

ANRO Price History

Loading...
52-Week Range61% of range
Current
$27.12
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--

ANRO Valuation

Market Cap
Market Cap Rank
#6,526
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)

ANRO Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--

ANRO Corporate Info

Phone Number
650 200 0412
Address
650 Castro Street
Suite 450
Mountain View, CA 94041
Country
Year Founded

ANRO Filings

Filing Date
Tuesday, November 10, 2026
Period Date
Wednesday, September 30, 2026
Next Filing
Week of Mar 15 and 19 (est)

ANRO Headlines

11/10/2026 - SeekingAlpha.com: All News